Replimune Group (REPL) Cut to Sell at Zacks Investment Research

Zacks Investment Research cut shares of Replimune Group (NASDAQ:REPL) from a hold rating to a sell rating in a research note published on Tuesday.

According to Zacks, “Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company’s product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United States. “

Shares of NASDAQ REPL traded up $0.26 during midday trading on Tuesday, hitting $10.88. The stock had a trading volume of 32,965 shares, compared to its average volume of 74,689. Replimune Group has a 52 week low of $8.88 and a 52 week high of $23.55.



Replimune Group (NASDAQ:REPL) last released its earnings results on Wednesday, November 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06). On average, research analysts anticipate that Replimune Group will post -1.21 earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Omega Fund Management LLC bought a new stake in shares of Replimune Group during the third quarter worth approximately $82,166,000. Bain Capital Life Sciences Investors LLC bought a new stake in shares of Replimune Group in the third quarter valued at approximately $45,707,000. Redmile Group LLC bought a new stake in shares of Replimune Group in the third quarter valued at approximately $35,307,000. Foresite Capital Management IV LLC bought a new stake in shares of Replimune Group in the third quarter valued at approximately $19,797,000. Finally, Foresite Capital Management III LLC bought a new stake in shares of Replimune Group in the third quarter valued at approximately $12,552,000. 55.75% of the stock is currently owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Further Reading: How To Calculate Debt-to-Equity Ratio

Get a free copy of the Zacks research report on Replimune Group (REPL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply